Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Economic Affairs Director Of Japan’s MHLW Comments On Daiichi Sankyo's Buyout Of Ranbaxy

This article was originally published in PharmAsia News

Executive Summary

Commenting on Daiichi Sankyo's buyout of Ranbaxy, Toshihiko Takeda, the economic affairs director of the Ministry of Health, Labor and Welfare's Health Policy Bureau, said he was surprised but thought as a new drug developer, Daiichi Sankyo took a step in the right direction to further expand overseas in a more competitive market. Even though it is still too early to judge how the generics market will develop in Japan, if after the merger Daiichi Sankyo decides to enter the generics market in Japan, it will have credibility as a major drug maker combined with low production costs in India. The legitimacy of the company's generics unit could contribute to the expansion of generic utilization in Japan. (Click here for more - Japanese language) "Economic Affairs Director Toshihiko Takeda Comments on Daiichi Sankyo's Buyout Of Ranbaxy" - Yakuji News (6/11/08)

You may also be interested in...

P&G Tapping Into UK Vegan Trend Via Nature’s Best

Procter & Gamble, through its UK wellness subsidiary Nature's Best, is on-trend with new vegan vitamin D3 and iron supplements. Nature's Best has also launched three other vitamin D3 products in the country, as well as an ashwagandha supplement. 

UK Shares How Its Medtech Regs Already Diverge From The EU: COVID-19 Marks The Start

The MHRA has updated its guidance on regulatory flexibilities for medical devices and medicinal products resulting from COVID-19 to highlight how its approach differs from the EU.

Carag Applies Bioabsorbable Material Technology To Transseptal Occluders

The Swiss company is planning a US trial of CBSO, the first transcatheter septal occluder with a bioresorbable, metal-free frame.




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts